Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.

Regeneron Pharmaceuticals (REGN) shares tanked this morning as the biotech firm announced its highly anticipated Phase 3 trial evaluating an experimental skin cancer combination therapy failed to meet its primary endpoint.

The late-stage trial REGN’s fianlimab (LAG-3 inhibitor), combined with its established immuno-therapy Libtayo, against Merck’s (MRK) blockbuster standard-of-care, Keytruda, in over 1,500 advanced melanoma patients.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.